Abstract
The impact of state-level medical cannabis laws (MCL) on individual-level opioid outcomes is inconclusive. We analyzed representative samples of U.S. adults ≥ 21 years reporting past-year non-medical prescription opioid (NMPO) use in the 2004–2014 National Surveys on Drug Use and Health. Multi-level mixed effects models estimated associations of state-level MCL with individual-level NMPO use frequency, categorized as occasional (1–12 days), regular (13–52 days), or frequent (53–365 days). Further analyses stratified by past-year cannabis use and disorder (no use, use only, DSM-IV cannabis use disorder). MCL was associated with increases in occasional NMPO use (2.1% points, 95% CI: 0.5, 3.8) alongside reductions in regular (-0.6% points, 95% CI: -1.1, -0.1) and frequent NMPO use (-1.5% points, 95% CI: -2.7, -0.4). In stratified analyses, significant changes were observed only for adults with cannabis use disorder, including increases in occasional NMPO use (5.6% points, 95% CI: 1.5, 9.6) and decreases in frequent NMPO use (-4.9% points, 95% CI: -8.1, -1.8). The association of MCL with lower frequency of NMPO use was driven by individuals with cannabis use disorder, highlighting the importance of identifying tradeoffs of cannabis legalization as an intervention to reduce opioid-related harms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Psychiatric Association. (2000). Diagnostic and statistical Manual of Mental disorders: DSM-IV, 4th ed., text revision (4th ed.). American Psychiatric Association.
Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical Cannabis laws and opioid analgesic Overdose mortality in the United States, 1999–2010. JAMA Intern Med, 174(10), 1668–1673. https://doi.org/10.1001/jamainternmed.2014.4005.
Bradford, A. C., & Bradford, W. D. (2016). Medical Marijuana Laws Reduce Prescription Medication Use In Medicare Part D. Health Aff (Millwood), 35(7), 1230–1236. https://doi.org/10.1377/hlthaff.2015.1661.
Bradford, A. C., & Bradford, W. D. (2017). Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff (Millwood), 36(5), 945–951. https://doi.org/10.1377/hlthaff.2016.1135.
Bradford, A. C., & Bradford, D. (2018). W. The impact of Medical Cannabis legalization on prescription medication use and costs under Medicare Part D. In Journal of Law and Economics (Vol. 61).
Bradford, A. C., Bradford, W. D., Abraham, A., & Adams, B., G (2018). Association between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population. JAMA Internal Medicine, 178(5), 667. https://doi.org/10.1001/jamainternmed.2018.0266.
Caputi, T. L., & Humphreys, K. (2018). Medical Marijuana users are more likely to use prescription Drugs medically and nonmedically. Journal of Addiction Medicine, 12(4), 295–299. https://doi.org/10.1097/ADM.0000000000000405.
Center for Behavioral Health Statistics and Quality (2014). National Survey on Drug Use and Health: Methodological Resource Books. https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health.
Centers for Disease Control and Prevention (2018, August 31). 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States Surveillance Special Report. Surveillance Special Report; Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf.
Cerdá, M., Sarvet, A. L., Wall, M., Feng, T., Keyes, K. M., Galea, S., & Hasin, D. S. (2018). Medical marijuana laws and adolescent use of marijuana and other substances: Alcohol, cigarettes, prescription Drugs, and other illicit Drugs. Drug and Alcohol Dependence, 183, 62–68. https://doi.org/10.1016/j.drugalcdep.2017.10.021.
Cerdá, M., Mauro, C., Hamilton, A., Levy, N. S., Santaella-Tenorio, J., Hasin, D., Wall, M. M., Keyes, K. M., & Martins, S. S. (2020). Association between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder from 2008 to 2016. JAMA Psychiatry, 77(2), 165. https://doi.org/10.1001/jamapsychiatry.2019.3254.
Davis, C. S., & Lieberman, A. J. (2021). Laws limiting prescribing and dispensing of opioids in the United States, 1989–2019. Addiction, 116(7), 1817–1827. https://doi.org/10.1111/add.15359.
Gorfinkel, L. R., Stohl, M., Greenstein, E., Aharonovich, E., Olfson, M., & Hasin, D. (2020). Is Cannabis being used as a substitute for non-medical opioids by adults with problem substance use in the United States? A within-person analysis. Addiction, 116, 1113–1121. https://doi.org/10.1111/add.15228.
Gukasyan, N., & Strain, E. C. (2020). Relationship between cannabis use frequency and major depressive disorder in adolescents: Findings from the National Survey on Drug Use and Health 2012–2017. Drug and Alcohol Dependence, 208, 2012–2017. https://doi.org/10.1016/j.drugalcdep.2020.107867.
Han, B., Compton, W. M., Blanco, C., Crane, E., Lee, J., & Jones, C. M. (2017). Prescription opioid use, misuse, and Use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Annals of Internal Medicine, 167(5), 293–301. https://doi.org/10.7326/M17-0865.
Hasin, D. S., Sarvet, A. L., Cerdá, M., Keyes, K. M., Stohl, M., Galea, S., & Wall, M. M. (2017). US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana laws: 1991–1992 to 2012–2013. JAMA Psychiatry, 74(6), 579–588. https://doi.org/10.1001/jamapsychiatry.2017.0724.
Horwitz, J. R., Davis, C., McClelland, L., Fordon, R., & Meara, E. (2020). The importance of data source in prescription drug monitoring program research. Health Services Research, 1–7. https://doi.org/10.1111/1475-6773.13548.
Ishida, J. H., Wongid, P. O., Cohen, B. E., Vali, M., Steigerwald, S., & Keyhaniid, S. (2019). Substitution of marijuana for opioids in a national survey of US adults. PLoS One, 14(10), e0222577. https://doi.org/10.1371/journal.pone.0222577.
McGinty, E. E., Bicket, M. C., Seewald, N. J., Stuart, E. A., Alexander, G. C., Barry, C. L., McCourt, A. D., & Rutkow, L. (2022). Effects of State Opioid Prescribing laws on Use of Opioid and other Pain treatments among commercially insured U.S. adults. Annals of Internal Medicine, 175(5), 617–627. https://doi.org/10.7326/m21-4363.
McMichael, B. J., Van Horn, R. L., & Viscusi, W. K. (2020). The impact of cannabis access laws on opioid prescribing. Journal of Health Economics, 69, 1–18. https://doi.org/10.1016/J.JHEALECO.2019.102273.
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018). Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD012182.pub2.
Olfson, M., Wall, M. M., Liu, S. M., & Blanco, C. (2018). Cannabis Use and risk of prescription opioid use disorder in the United States. American Journal of Psychiatry, 175(1), 47–53. https://doi.org/10.1176/appi.ajp.2017.17040413.
Pacula, R. L., & Smart, R. (2017). Medical marijuana and marijuana legalization. Annual Review of Clinical Psychology, 13, 397–419. https://doi.org/10.1146/annurev-clinpsy-032816-045128.
Powell, D., Pacula, R. L., & Jacobson, M. (2018). Do medical marijuana laws reduce addictions and deaths related to pain killers? Journal of Health Economics, 58, 29–42. https://doi.org/10.1016/j.jhealeco.2017.12.007.
Rabe-Hesketh, S., & Skrondal, A. (2006). Multilevel modelling of complex survey data. In Journal of the Royal Statistical Society (Vol. 169).
Reiman, A., Welty, M., & Solomon, P. (2017). Cannabis as a substitute for opioid-based Pain Medication: Patient self-report. Cannabis and Cannabinoid Research, 2(1), 160–166. https://doi.org/10.1089/can.2017.0012.
Schmid, I., Stuart, E. A., McCourt, A. D., Tormohlen, K. N., Stone, E. M., Davis, C. S., Bicket, M. C., & McGinty, E. E. (2022). Effects of state opioid prescribing cap laws on opioid prescribing after Surgery. Health Services Research, 57(5), 1154–1164. https://doi.org/10.1111/1475-6773.14023.
Segura, L. E., Mauro, C. M., Levy, N. S., Khauli, N., Philbin, M. M., Mauro, P. M., & Martins, S. S. (2019). Association of US medical marijuana laws with nonmedical prescription opioid use and prescription opioid use disorder. JAMA Network Open, 2(7), e197216. https://doi.org/10.1001/jamanetworkopen.2019.7216.
Shover, C. L., Davis, C. S., Gordon, S. C., Humphreys, K., & Wachter, K. W. (2019). Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1903434116.
Spencer, M. R., Miniño, A. M., & Warner, M. (2022). Drug Overdose deaths in the United States, 2001–2021. Nchs Data Brief, 457.
StataCorp. (2019). Stata Statistical Software: Release 16. StataCorp LLC. No. 15.
Stone, E. M., Tormohlen, K. N., McCourt, A. D., Schmid, I., Stuart, E. A., Davis, C. S., Bicket, M. C., & McGinty, E. E. (2022). Association between State Opioid Prescribing Cap laws and receipt of opioid prescriptions among children and adolescents. JAMA Health Forum, 3(8), e222461. https://doi.org/10.1001/jamahealthforum.2022.2461.
United States Census Bureau. (2010). 2010 Census. U.S. Census Bureau.
Wen, H., & Hockenberry, J. M. (2018). Association of Medical and Adult-Use Marijuana laws with Opioid Prescribing for Medicaid Enrollees. JAMA Internal Medicine, 178(5), 673–679. https://doi.org/10.1001/jamainternmed.2018.1007.
Wen, H., Hockenberry, J. M., & Cummings, J. R. (2015). The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. Journal of Health Economics, 42, 64–80. https://doi.org/10.1016/J.JHEALECO.2015.03.007.
Wen, J., Wen, H., Butler, J. S., & Talbert, J. C. (2021). The impact of medical and recreational marijuana laws on opioid prescribing in employer-sponsored health insurance. Health Economics, 30(5), 989–1000. https://doi.org/10.1002/hec.4237.
Wiese, B., & Wilson-Poe, A. R. (2018). Emerging evidence for Cannabis’ Role in Opioid Use Disorder. Cannabis and Cannabinoid Research, 3(1), 179–189. https://doi.org/10.1089/can.2018.0022.
Wilson, J., Mills, K., Freeman, T. P., Sunderland, M., Visontay, R., & Marel, C. (2021). Weeding out the truth: A systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence. Addiction. https://doi.org/10.1111/add.15581.
Wong, S. S. C., Chan, W. S., & Cheung, C. W. (2020). Analgesic effects of cannabinoids for Chronic Non-cancer Pain: A systematic review and Meta-analysis with Meta-regression. Journal of Neuroimmune Pharmacology, 15, 801–829. https://doi.org/10.1007/s11481-020-09905-y.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Samples, H., Levy, N.S., Bruzelius, E. et al. Association Between Legal Access to Medical Cannabis and Frequency of Non-Medical Prescription Opioid Use Among U.S. Adults. Int J Ment Health Addiction (2023). https://doi.org/10.1007/s11469-023-01191-y
Accepted:
Published:
DOI: https://doi.org/10.1007/s11469-023-01191-y